Low Expression of Excision Repair Cross-complementation Group-1 Protein Predicts Better Outcome in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Concurrent Chemoradiotherapy

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

(2012) Jong-Mu Sun et al.   BMC CANCER

Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy

(2012) Pei-Yu Huang et al.   ORAL ONCOLOGY

Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy

(2011) Jong-Mu Sun et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

(2009) Koichi Azuma et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation

(2008) H J Jun et al.   BRITISH JOURNAL OF CANCER

ERCC1expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

(2008) In Gyu Hwang et al.   CANCER

High ERCC1 Expression is Associated with Worse Survival in Patients with Locally Advanced Cervical Cancer Treated with Radiotherapy (RT): an Evaluation of AQUA® Versus Conventional IHC Methods

(2008) C.M. Doll et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer

(2007) Min Kyoung Kim et al.   EUROPEAN JOURNAL OF CANCER